525 related articles for article (PubMed ID: 33811822)
1. COVID-19 vaccines for patients with haematological conditions.
Sun C; Pleyer C; Wiestner A
Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
[No Abstract] [Full Text] [Related]
2. Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
Kamboj M
Lancet Haematol; 2021 Aug; 8(8):e540-e542. PubMed ID: 34224666
[No Abstract] [Full Text] [Related]
3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
4. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Schmitt AM; Tippu Z; Farag S; Rogiers A; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Barber T; Emslie-Henry A; Caulfield-Lynch N; Byrne F; Shum B; Gerard CL; Deng D; Kjaer S; Song OR; Queval C; Kavanagh C; Wall EC; Carr EJ; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Shea RL; Gardner G; Murray D; Yousaf N; Jhanji S; Van As N; Young K; Furness AJS; Pickering L; Beale R; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Howell M; Nicholson E; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
Cancer Cell; 2022 Feb; 40(2):114-116. PubMed ID: 34968417
[No Abstract] [Full Text] [Related]
5. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
Normark J; Vikström L; Gwon YD; Persson IL; Edin A; Björsell T; Dernstedt A; Christ W; Tevell S; Evander M; Klingström J; Ahlm C; Forsell M
N Engl J Med; 2021 Sep; 385(11):1049-1051. PubMed ID: 34260850
[No Abstract] [Full Text] [Related]
6. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
Malard F; Gaugler B; Gozlan J; Bouquet L; Fofana D; Siblany L; Eshagh D; Adotevi O; Laheurte C; Ricard L; Dulery R; Stocker N; van de Wyngaert Z; Genthon A; Banet A; Memoli M; Ikhlef S; Sestilli S; Vekhof A; Brissot E; Marjanovic Z; Chantran Y; Cuervo N; Ballot E; Morand-Joubert L; Mohty M
Blood Cancer J; 2021 Aug; 11(8):142. PubMed ID: 34376633
[TBL] [Abstract][Full Text] [Related]
7. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
[No Abstract] [Full Text] [Related]
8. How nano can fight the virus.
Ball P
Nat Mater; 2021 Feb; 20(2):126. PubMed ID: 33504984
[No Abstract] [Full Text] [Related]
9. [Vaccination immunology in SARS-CoV-2].
Helweg-Larsen J; Benfield T
Ugeskr Laeger; 2021 Mar; 183(11):. PubMed ID: 33734074
[TBL] [Abstract][Full Text] [Related]
10. Messenger RNA vaccines against SARS-CoV-2.
Topol EJ
Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Meylan P
Rev Med Suisse; 2020 Oct; 16(709):1895. PubMed ID: 33026736
[No Abstract] [Full Text] [Related]
12. Mounting evidence suggests Sputnik COVID vaccine is safe and effective.
Nogrady B
Nature; 2021 Jul; 595(7867):339-340. PubMed ID: 34230663
[No Abstract] [Full Text] [Related]
13. Vaccine against SARS-CoV-2 in previously infected health care workers.
Parisi SG
EBioMedicine; 2021 Sep; 71():103556. PubMed ID: 34454402
[No Abstract] [Full Text] [Related]
14. Safety of mRNA-Based Vaccines for SARS CoV-2.
Barda B; Cerny A
Chem Res Toxicol; 2021 Aug; 34(8):1823-1825. PubMed ID: 34009959
[TBL] [Abstract][Full Text] [Related]
15. The lightning-fast quest for COVID vaccines - and what it means for other diseases.
Ball P
Nature; 2021 Jan; 589(7840):16-18. PubMed ID: 33340018
[No Abstract] [Full Text] [Related]
16. COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.
He Q; Mao Q; Zhang J; Bian L; Gao F; Wang J; Xu M; Liang Z
Front Immunol; 2021; 12():669339. PubMed ID: 33912196
[TBL] [Abstract][Full Text] [Related]
17. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
Krammer F; Srivastava K; Alshammary H; Amoako AA; Awawda MH; Beach KF; Bermúdez-González MC; Bielak DA; Carreño JM; Chernet RL; Eaker LQ; Ferreri ED; Floda DL; Gleason CR; Hamburger JZ; Jiang K; Kleiner G; Jurczyszak D; Matthews JC; Mendez WA; Nabeel I; Mulder LCF; Raskin AJ; Russo KT; Salimbangon AT; Saksena M; Shin AS; Singh G; Sominsky LA; Stadlbauer D; Wajnberg A; Simon V
N Engl J Med; 2021 Apr; 384(14):1372-1374. PubMed ID: 33691060
[No Abstract] [Full Text] [Related]
18. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
[TBL] [Abstract][Full Text] [Related]
19. Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed.
Figueroa JP; Hotez PJ; Batista C; Ben Amor Y; Ergonul O; Gilbert S; Gursel M; Hassanain M; Kang G; Kaslow DC; Kim JH; Lall B; Larson H; Naniche D; Sheahan T; Shoham S; Wilder-Smith A; Sow SO; Strub-Wourgaft N; Yadav P; Bottazzi ME
PLoS Med; 2021 Sep; 18(9):e1003772. PubMed ID: 34516558
[TBL] [Abstract][Full Text] [Related]
20. Audio Interview: The Implications of Changes in the Structural Biology of SARS-CoV-2.
Rubin EJ; Baden LR; Abraham J; Morrissey S
N Engl J Med; 2021 Mar; 384(10):e48. PubMed ID: 33704945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
